Zydus Lifesciences Ordered to Pay Deficient Stamp Duty, Fines for Asset Acquisition
NiveshIQ
NSE: ZYDUSLIFE · Healthcare
Zydus Lifesciences Ltd.
₹1,122.70▲ ₹23.50 (+2.14%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ZYDUSLIFE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Zydus Lifesciences Ltd.
Zydus Lifesciences Limited is a prominent player in the Indian healthcare sector, with a diversified portfolio of pharmaceutical products, consumer wellness, and animal health offerings. The company operates through two segments: Pharmaceuticals and Consumer Products, catering to domestic and international markets. Its product range includes active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, and consumer wellness products under various brands. Zydus Lifesciences has a robust pipeline of biological products in areas such as oncology, autoimmune disease, and infectious illnesses. The company has recently reported a record revenue of ₹27,148 Cr and a net income of ₹5,040 Cr. Notably, Zydus Lifesciences has made significant strides in s
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹19,548 Cr +13.40% | ₹23,242 Cr +18.90% | ₹27,148 Cr +16.80% |
| EBITDA Margin | 27.54% | 31.53% | 33.09% |
| Net Profit | ₹3,973 Cr +89.90% | ₹4,834 Cr +21.70% | ₹5,543 Cr +14.70% |
| EPS | ₹38.20 | ₹44.98 | ₹50.09 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Zydus Lifesciences faces ₹108.54 million stamp duty demand
Zydus Lifesciences Ltd slips for fifth straight session
🔒
+ 3 more stories about Zydus Lifesciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹7, 587 Cr, PAT ₹1, 739 Cr, EPS ₹12.65, EBITDA margin 35.4%. Growth context: revenue YoY +16.2%, PAT YoY +18.4%, revenue QoQ +10.5%, PAT QoQ +70.0%. Street verdict: strong beat, revenue surprise +3.9%, PAT surprise +18.6%.
Product launches, approvals, and therapy-mix improvement are key near-term growth drivers for Zydus Lifesciences, with t...
FY26 (last completed FY): revenue ₹27, 148 Cr, PAT ₹5, 543 Cr, EBITDA margin 33.1%, EPS ₹50.09. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ZYDUSLIFE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ZYDUSLIFE alongside your other holdings
Unlock full ZYDUSLIFE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Zydus Lifesciences Ltd.?
NiveshIQ detects active intelligence signals for Zydus Lifesciences Ltd. (ZYDUSLIFE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Zydus Lifesciences Ltd.?
Zydus Lifesciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹9,458,599.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.